Results for gvhd translation from Danish to English

akut gvhd blev
the incidence of a- gvhd grades i-ii was 13% (8/ 61), while the incidence of grade iii-iv was 5% (3/ 61).

profylakse for gvhd
prophylaxis in gvhd

ii - iv gvhd gvhd
ii - iv gvhd gvhd

akut gvhd kronisk gvhd
acute graft versus host disease chronic graft versus host disease

akut grad ii - iv gvhd
acute grade ii - iv gvhd

gvhd, hvor systemisk immunsupprimerende behandling er nødvendig.
gvhd requiring systemic immunosupressive therapy.

hvis gvhd opstår, skal der administreres gcv/vcv.
if gvhd occurs, gcv/vcv will be administered.

11 patienter i alt (18 %) fik a-gvhd.
a total of 11 patients (18%) experienced a-gvhd.

en patient med grad 1 akut gvhd fik ikke nogen behandling.
one patient with grade 1 acute gvhd did not receive any treatment.

der var ingen gvhd-relaterede dødsfald eller langvarige komplikationer.
there were no gvhd-related deaths or long-term complications.

alle tilfælde af akut gvhd var helt ophørt efter en median varighed på 12 dage.
all acute gvhd events fully resolved after a median duration of 12 days.

både akut og kronisk gvhd udvikledes kun hos patienter, som havde opnået immunrekonstitution.
both acute and chronic gvhd events developed only in patients who had achieved immune reconstitution.

kriterier for at få zalmoxis-infusioner inkluderede fravær af både immunrekonstitution og gvhd.
criteria for receiving zalmoxis infusions included the lack of both immune reconstitution and gvhd.

graft versus host-sygdom (gvhd) er også blevet rapporteret.
graft versus host disease (gvhd) has also been reported.

alle tegn og symptomer på grad 2 til 4 akut eller svær kronisk gvhd var helt ophørt efter en median behandlingsvarighed af gcv eller vcv på 15 dage.
all signs and symptoms of grade 2 to 4 acute and extensive chronic gvhd fully resolved after a median treatment duration of gcv or vcv of 15 days.

den hyppigste bivirkning, som blev rapporteret af patienter, behandlet med zalmoxis i det kliniske studie tk007, var akut gvhd.
the most common adverse reaction reported by patients treated with zalmoxis in clinical trial tk007 was acute gvhd.

de aktiverede, transducerede t-lymfocytter, som forårsager gvhd, konverterer gcv til dets toksiske form og undergår derved apoptose.
the activated, transduced t lymphocytes that are causing the gvhd should convert the gcv to its toxic form and thereby undergo apoptosis.

forekomsten af a- gvhd grad i-ii var 13 % (8/61), mens forekomsten af grad iii-iv var 5 % (3/61).
the incidence of a-gvhd grades i-ii was 13% (8/61), while the incidence of grade iii-iv was 5% (3/61).